News
Drug for metastatic cervical cancer approved by the European Commission
The treatment was able to reduce the risk of death by 31 per cent compared to chemotherapy during study

A drug that demonstrated significant survival benefit in patients with recurrent or metastatic cervical cancer has been approved by the European Commission.
Regeneron Pharmaceuticals has announced that the European Commission (EC) approved Libtayo (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
The EC approval in advanced cervical cancer is based on data from the global phase 3 trial, which was conducted with the GOG Foundation, the European Network for Gynaecological Oncological Trial groups (ENGOT) and NRG Oncology-Japan.
The trial evaluated Libtayo in comparison to an investigator’s choice of chemotherapy and enrolled 608 patients across 14 countries, irrespective of PD-L1 expression status or histology.
In March 2021, the trial was stopped early based on the highly significant effect of Libtayo on overall survival (OS) among squamous cell carcinoma (SCC) patients following a unanimous recommendation by the Independent Data Monitoring Committee.
“Despite recent advancements in the prevention and treatment of cervical cancer, there remain limited options for people with recurrent or metastatic cases,” said Israel Lowy, senior vice president at Regeneron.
“Libtayo was the first PD-1 inhibitor to demonstrate significant improvements in survival compared to chemotherapy in a Phase 3 trial.
“With this fourth approval from the European Commission, Libtayo can now be extended to appropriate patients in the European Union with advanced cervical cancer, irrespective of their PD-L1 status or histology.”
Professor Ignace Vergote, investigator and gynaecologist oncologist at University Hospitals Leuven in Belgium, and vice-chair of the Trial Steering Committee, said: “Consistent with our mission to bring the best treatments to patients across Europe living with gynaecological cancers, we are proud to have been a part of this landmark trial for Libtayo.
“Libtayo is an important advancement for patients with recurrent or metastatic cervical cancer whose disease has progressed following platinum-based chemotherapy and could offer a new standard of care in this setting.
“We are grateful to those who participated in the trial and to our partners at Regeneron, ENGOT, the GOG Foundation and NRG Oncology-Japan without whom this approval would not have been possible.”
Cervical cancer is the fourth leading cause of cancer death in women worldwide and is most frequently diagnosed between the ages of 35 and 44.
Approximately 600,000 new cases of cervical cancer and 350,000 deaths from cervical cancer occur worldwide each year.
Almost all cases are caused by human papillomavirus (HPV) infection, with approximately 80 per cent classified as squamous cell carcinoma – arising from cells lining the external portion of the cervix – and the remainder largely adenocarcinomas – arising from glandular cells lining the internal portion of the cervix.
Cervical cancer is often curable when detected early and effectively managed, but treatment options are more limited in advanced stages.
In addition, Libtayo has also been approved in the EU for the treatment of three other types of cancer, including certain patients with advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC) and advanced non-small cell lung cancer (NSCLC).
News
Resistance training has preventative effects in menopause, study finds

Resistance training improves hip strength, balance and flexibility during menopause and may also improve lean body mass, research suggests.
A study of 72 active women aged 46 to 57 found those who completed a 12-week supervised programme saw greater gains than those who kept to their usual exercise routines.
None of the participants were taking hormone replacement therapy.
The supervised, low-impact resistance exercise programme focused on strength at the hip and shoulder, dynamic balance and flexibility.
Participants used Pvolve equipment, including resistance bands and weights around the hips, wrists and ankles, and also lifted dumbbells of varying loads.
Women in the resistance training group showed a 19 per cent increase in hip function and lower-body strength, a 21 per cent increase in full-body flexibility and a 10 per cent increase in dynamic balance, meaning the ability to stay stable while moving.
Those in the usual activity group did not show any significant improvements.
Previous studies have assessed the decline in lower limb strength and flexibility during menopause, but this is said to be the first study to compare the effect of resistance training on muscle strength and mass before, during and after menopause.
This was done by including participants in different phases of menopause rather than following the same participants over a long timeframe.
Francis Stephens, a researcher at the University of Exeter Medical School in the UK, said: “These results are important because women appear to be more susceptible to loss of leg strength as they age, particularly after menopause, which can lead to increased risk of falls and hip fractures.
“This is the first study to demonstrate that a low-impact bodyweight and resistance band exercise training programme with a focus on the lower limbs, can increase hip strength, balance, and flexibility.
“Importantly, these improvements were the same in peri- and post-menopausal females when compared to pre-menopausal females, suggesting that changes associated with menopause do not mitigate the benefits of exercise.”
Although one of the researchers sits on Pvolve’s clinical advisory board, the researchers said the company did not sponsor the study or influence its results.
Stephens added that any progressive resistance exercise training focused on lower-body strength is likely to yield the same results.
He said: “The important point is for an individual to find a type of exercise, modality, location, time of day etc., that is enjoyable, sustainable, and improves everyday life.
“The participants in the present study reported an improvement in ‘enjoyment of exercise,’ and some are still using the programme since the study finished.”
Kylie Larson, a women’s health and fitness coach and founder of Elemental Coaching, who was not involved in the study, said the results were compelling.
She said: “This is particularly exciting for those that tend to think of menopause as ‘the end’. The study proves that if you incorporate strength training you can still make improvements to your muscle mass and strength, which will also have a positive ripple effect to your ability to manage your body composition.
“In addition, staying flexible and being able to balance are both keys to a healthy and functional second half of life.”
Participants in the study did four classes a week for 30 minutes each session, but Larson said even half that amount of strength training can go a long way, particularly if you emphasise progressive overload, which means gradually increasing muscle challenge through more weight.
Larson said: “Gradually increasing the challenge is what drives real change.
“Lifting heavier over time is what builds strength, protects your bones, and keeps your body resilient through menopause and beyond.”
Wellness
France to reimburse young women for cost of reusable period products
News
Condé Nast to close women’s health magazine after 47 years

Condé Nast will close its women’s health publication Self after 47 years, with unprofitable editions of Glamour and Wired also set to shut.
In a memo published on the magazine giant’s website on Thursday, the media company’s chief executive, Roger Lynch, said: “As audience behaviours shift, we have not seen a path for Self to continue in its current form as a digital publication.”
“Going forward, health and wellness content will be integrated into our other brands, including Allure and Glamour,” Lynch said, referring to Condé Nast’s other beauty and wellness titles.
Self, which moved to an online-only format in 2017, still reaches more than 20m people each month.
The publication has also earned significant recognition over the years, including a National Magazine award and a Webby’s People’s Voice award.
The closure is part of a wider set of operational changes across the company. Lynch also announced the end of Wired’s Italy edition, noting that while the brand “remains a strong global brand, the Italian edition has not kept pace with growth in our other markets”.
Condé Nast will also wind down Glamour’s publishing operations in Germany, Spain and Mexico.
Lynch said: “Taken together, Wired in Italy, Self and the affected Glamour markets represent a little over 1 per cent of our overall revenue.
“They also remain unprofitable, and continuing to operate them in their current form limits our ability to invest in the ideas and areas that will drive future growth.”
Beyond editorial changes, the company is also restructuring internally to adapt to technological shifts.
Lynch said Condé Nast would make “changes within our technology organisation, reflecting the rapid advancement of AI and its impact on our ability to innovate and build products faster”, adding: “Teams will be restructured to be more agile and to work more closely with our brands and customers, reducing barriers to execution.”
The latest moves follow a series of transformations at Condé Nast in recent years.
Glamour ended its print edition in 2018, followed by Allure moving to a digital-only format in 2022.
In 2024, music publication Pitchfork was folded into GQ, the company’s men’s style magazine.
More recently, last November, Vogue, one of Condé Nast’s key revenue drivers, announced it would absorb Teen Vogue to create a more “unified reader experience across titles”.
The media industry has been shrinking steadily over the years.
From 2010 to 2017, the industry lost an average of 7,305 jobs annually, according to data from Challenger, Gray & Christmas published in December 2025.
Since 2018, the average number of job cuts in the industry has risen to 14,298 a year.
Entrepreneur3 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Menopause4 weeks agoCalifornia plans US$3.4m menopause care overhaul
Pregnancy3 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
Menopause4 weeks agoWatchdog bans five ads for women’s heath claims
Entrepreneur4 weeks agoWHIS USA 2026 announces first ticket release for landmark Women’s Health Innovation Summit
Mental health4 weeks agoMenopause has no lasting impact on cognition, research finds
News3 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Opinion3 weeks agoQ1 momentum: Female founders are advancing, but the system still hasn’t caught up














1 Comment